Page last updated: 2024-09-05

lapatinib and camptothecin

lapatinib has been researched along with camptothecin in 13 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(camptothecin)
Trials
(camptothecin)
Recent Studies (post-2010) (camptothecin)
1,9193051,44213,0022,2295,391

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)camptothecin (IC50)
Histone deacetylase 3Homo sapiens (human)0.05
Multidrug resistance-associated protein 4Homo sapiens (human)7.4
DNA topoisomerase 1Homo sapiens (human)1.9799
Somatostatin receptor type 1Homo sapiens (human)0.0022
Somatostatin receptor type 2Homo sapiens (human)0.0022
Somatostatin receptor type 4Homo sapiens (human)0.0022
Somatostatin receptor type 3Homo sapiens (human)0.0022
Somatostatin receptor type 5Homo sapiens (human)0.0022
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.97
Histone deacetylase 4Homo sapiens (human)0.05
Histone deacetylase 1Homo sapiens (human)0.05
Histone deacetylase 7Homo sapiens (human)0.05
Histone deacetylase 2Homo sapiens (human)0.05
Polyamine deacetylase HDAC10Homo sapiens (human)0.05
Histone deacetylase 11 Homo sapiens (human)0.05
Histone deacetylase 8Homo sapiens (human)0.05
Histone deacetylase 6Homo sapiens (human)0.05
Histone deacetylase 9Homo sapiens (human)0.05
Histone deacetylase 5Homo sapiens (human)0.05

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (23.08)29.6817
2010's6 (46.15)24.3611
2020's4 (30.77)2.80

Authors

AuthorsStudies
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR1
Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR1
Liu, Y; Xu, Z; Zhao, SJ1
Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR1
Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C1
Dean-Colomb, W; Esteva, FJ1
Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Manegold, PC; Wilson, PM1
Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y1
Hasegawa, T; Hirakawa, K; Matsuzaki, T; Qiu, H; Yashiro, M; Zhang, X1
Camidge, DR; Danysh, HE; Hackshaw, MD; Iwata, H; Ladner, A; Powell, CA; Ritchey, ME; Singh, J; Taitt, C1
Freeman, MR; Hemler, ME; Sharma, C; Steen, H; Yang, W1
Gelmon, KA; Tesch, ME1

Reviews

4 review(s) available for lapatinib and camptothecin

ArticleYear
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles

2019
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
    Seminars in oncology, 2008, Volume: 35, Issue:2 Suppl 2

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine

2008
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
    Breast cancer research and treatment, 2020, Volume: 183, Issue:1

    Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Disease Management; Drug Monitoring; Everolimus; Female; Humans; Immunoconjugates; Incidence; Lapatinib; Lung Diseases, Interstitial; Neoplasm Metastasis; Paclitaxel; Pneumonia; Receptor, ErbB-2; Trastuzumab

2020
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
    Drugs, 2020, Volume: 80, Issue:17

    Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab

2020

Trials

1 trial(s) available for lapatinib and camptothecin

ArticleYear
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Lapatinib; Leucovorin; Male; Middle Aged; Neoplasms; Quinazolines; Tandem Mass Spectrometry

2007

Other Studies

8 other study(ies) available for lapatinib and camptothecin

ArticleYear
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
Highly predictive and interpretable models for PAMPA permeability.
    Bioorganic & medicinal chemistry, 2017, 02-01, Volume: 25, Issue:3

    Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine

2017
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
    Bioorganic & medicinal chemistry, 2019, 07-15, Volume: 27, Issue:14

    Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility

2019
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
    Scientific reports, 2020, 11-26, Volume: 10, Issue:1

    Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States

2020
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
    International journal of cancer, 2009, Dec-15, Volume: 125, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Chromatography, Liquid; Colonic Neoplasms; Colony-Forming Units Assay; Drug Synergism; ErbB Receptors; Flow Cytometry; Humans; Irinotecan; Lapatinib; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2009
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays

2010
An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
    British journal of cancer, 2011, Nov-08, Volume: 105, Issue:10

    Topics: Animals; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Irinotecan; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Stomach Neoplasms

2011
Antioxidant functions of DHHC3 suppress anti-cancer drug activities.
    Cellular and molecular life sciences : CMLS, 2021, Volume: 78, Issue:5

    Topics: Acyltransferases; Antineoplastic Agents; Antioxidants; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Female; Gefitinib; Humans; Lapatinib; Male; Prostatic Neoplasms; RNA Interference

2021